Acrivon Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Acrivon Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Precision oncology biotech with validated biomarker platform and potentially registrational Phase 2b data in underserved endometrial cancer segment, but faces typical pre-commercial biotech risks. Market Cap is approximately $77M with significant clinical validation (FDA Fast Track designation, Breakthrough Device designation). Recent clinical data demonstrates meaningful efficacy signals, though company.
What is Acrivon Therapeutics, Inc.'s industry? Acrivon Therapeutics, Inc. (acrivon.com) operates in Precision Oncology / Biopharmaceuticals. AskCyborg classifies Acrivon Therapeutics, Inc. under Precision Oncology / Biopharmaceuticals in its company registry.
Acrivon is a clinical stage biopharmaceutical company discovering and developing precision oncology medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. Its lead clinical candidate is ACR-368...
Cyborg Score thesis
Precision oncology biotech with validated biomarker platform and potentially registrational Phase 2b data in underserved...
Read the full analyst-debate transcript →Get the Latest Acrivon Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAcrivon Therapeutics, Inc. Overview
Pro stress-test →Acrivon is a clinical stage biopharmaceutical company discovering and developing precision oncology medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, with recent data showing strong activity particularly in serous endometrial cancer.
Strategic Profile
Pro stress-test →Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer, and has received Fast Track designation from the FDA. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment. The company leverages proprietary biomarker-driven precision medicine to differentiate its approach in competitive oncology markets.
Competitive Landscape
Pro stress-test →Acrivon competes in precision oncology oncology space against larger biotech and pharma companies developing CHK1/CHK2 inhibitors and WEE1 inhibitors. Key differentiator is the proprietary phosphoproteomics-based companion diagnostic (OncoSignature) enabling biomarker-driven patient selection. Competitors include emerging biotech focused on cell cycle checkpoint inhibition and gynecological oncology specialists.
Industry Context
Acrivon Therapeutics, Inc. operates in Precision Oncology / Biopharmaceuticals.
Key facts
Founded: 2018 · Headquarters: Watertown, Massachusetts · Employees: Unknown · Revenue: Pre-revenue · Market cap: $77M